{"gao_id": "GAO-18-80", "published": "2017-12-14T12:00:00Z", "released": "2018-01-16T07:00:00Z", "summary": "Generic drugs can save consumers and the health care system billions of dollars. But it can be challenging for drug companies to prove to the Food and Drug Administration that generic versions of certain complex drugs are the same as their brand-name counterparts. To help, the agency issues guidance documents providing recommendations on how to demonstrate equivalence. However, we found that FDA issues new guidance...", "title": "Generic Drugs: FDA Should Make Public Its Plans to Issue and Revise Guidance on Nonbiological Complex Drugs", "topics": ["Biologics", "Manufacturing", "Pharmaceutical industry", "User fees", "Health Care", "Health care standards", "Product development", "Drugs", "Biological products", "Generic drugs", "Health care"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-18-80", "versions": [{"title": "Highlights Page (1 page)", "url": "https://www.gao.gov/assets/gao-18-80-highlights.pdf"}, {"title": "Full Report (50 pages)", "url": "https://www.gao.gov/assets/gao-18-80.pdf"}, {"title": "Accessible PDF (53 pages)", "url": "https://www.gao.gov/assets/690/689319.pdf"}]}